Previous 10 | Next 10 |
CHONGQING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.’s (SZSE: 300363) fermentation pilot laboratory located in Porton’s Changshou site, achieving another impor...
REDWOOD CITY, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, have signed an agreement to a...
REDWOOD CITY, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis’ EvoT4 TM DNA ligase high-performance molecular diagnostic enzyme. This enzyme was developed using...
Preliminary data from a Phase 1/2 clinical trial, pheNIX , evaluating Homology Medicines' (NASDAQ: FIXX ) gene therapy HMI-102 in patients with phenylketonuria (PKU) showed encouraging action. More news on: Homology Medicines, Inc., Synlogic, Inc., BioMarin Pharmaceutical Inc., Healthc...
By digging through SEC filings of institutional shareholders, investors can unearth promising stocks hidden to most. Codexis (NASDAQ: CDXS) fits this bill. With a business focused on developing enzymes, Codexis has built a growing revenue stream through partnerships and licenses to its ...
REDWOOD CITY, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the prestigious peer-reviewed journal Science , detailing the ...
Enzyme engineering leader Codexis (NASDAQ: CDXS) achieved a long-awaited milestone in the third quarter of 2019: positive operating income. Investors shouldn't expect it to become a trend due to the inherent choppiness of the business. In fact, the business reported a deeper operating loss t...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Image source: The Motley Fool. Codexis (NASDAQ: CDXS) Q3 2019 Earnings Call Nov 05, 2019 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...